Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024)

Historic Asset Writedowns and Impairment for Foghorn Therapeutics (FHTX) over the last 1 years, with Q2 2024 value amounting to $2.4 million.

  • Foghorn Therapeutics' Asset Writedowns and Impairment changed N/A to $2.4 million in Q2 2024 from the same period last year, while for Jun 2025 it was $2.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • Foghorn Therapeutics' Asset Writedowns and Impairment amounted to $2.4 million in Q2 2024.
  • Foghorn Therapeutics' 5-year Asset Writedowns and Impairment high stood at $2.4 million for Q2 2024, and its period low was $2.4 million during Q2 2024.